Brief: Lantern Pharma To Present Data Highlighting The Anti-Tumor Potency Of Drug Candidate Lp-284
31/08/2023 13:39
Aug 31 (Reuters) - Lantern Pharma Inc LTRN.O :
* LANTERN PHARMA TO PRESENT DATA HIGHLIGHTING THE ANTI-TUMOR
POTENCY OF DRUG CANDIDATE LP-284 IN NON-HODGKIN’S LYMPHOMAS AT
THE SOCIETY OF HEMATOLOGIC ONCOLOGY ANNUAL MEETING
* LANTERN PHARMA INC - LANTERN EXPECTS TO INITIATE PHASE 1
CLINICAL TRIALS FOR LP-284 DURING Q4 OF 2023
Source text for Eikon: ID:nBw4G9R10a
Further company coverage: LTRN.O
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Receives Taiwan Approvals To Open Next Stage Of Phase 2 Harmonic Trial Of Lp-300 In Never-Smoker, Egfr-Mutant Nsclc
Brief: Lantern Pharma Reports Second Quarter 2026 Financial Results And Provides Business Update
Lantern Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Lantern Pharma Q2 operating loss widens on warrant expenses tied to higher stock price
Lantern Pharma Inc expected to post a loss of 38 cents a share - Earnings Preview